Pharmaceutical firm Eli Lilly and Co. is expected to announce on Tuesday it “is pledging $30 million to help fight multidrug-resistant tuberculosis [MDR-TB] in developing countries, a disease that kills more than 150,000 people a year,” according to the Indianapolis Star. The funds, part of the company’s eight-year-old, $165 million Lilly MDR-TB Partnership, will help to “provide training for nurses, doctors and community volunteers; conduct studies on how to combat the disease; and provide access to medicines,” the newspaper notes. The campaign will focus on China, India, Russia and South Africa, “the four countries with the highest burden of MDR-TB, Lilly said,” the Indianapolis Star writes (10/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.